Skip to content
Bored Studies
RecruitingPhase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

argenx · NCT07091630

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
160
US sites recruiting
13
Study start
September 16, 2025
Record last updated
October 16, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emnergize

Being studied: Empasiprubart IV; Placebo IV

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
  • Has residual disability and active disease
  • Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)
  • Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP

Exclusion Criteria

  • Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Sensory CIDP (including sensory-predominant CIDP)
  • Polyneuropathy of other causes
  • Clinical diagnosis of systemic lupus erythematosus (SLE)
  • Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation

Recruiting US locations

  • University of Alabama at Birmingham - 1720 University Blvd

    Birmingham, AL 35233

    Site contact: Eroboghene Ubogu, MD · 857-350-4834 · clinicaltrials@argenx.com

  • Samir Macwan, M.D., Inc. (S corporation)

    Rancho Mirage, CA 92270

    Site contact: Samir Macwan, MD · 760-834-3540 · smacwan@southlandneuromuscular.com; samirmacwan@gmail.com

  • Colorado Springs Neurological Associates

    Colorado Springs, CO 80907

    Site contact: David Stevens, MD · 719-389-1159 · dstevens@csneuro.com

  • Medstar Health Research Institute

    Washington D.C., DC 20010

    Site contact: Yasir Al-Khalili, MD · 857-350-4834 · yasir.al-khalili@medstar.net

  • Gables Neurology

    Miami, FL 33133

    Site contact: Andrew Lerman, MD · 954-243-5559 · alerman@fcneurology.net

  • Aqualane Clinical Research

    Naples, FL 34105

    Site contact: Matthew Baker, MD · 650-723-6961 · Matthew@aqualaneresearch.com

  • Vero Beach Neurology and Research Institute

    Vero Beach, FL 32960-4806

    Site contact: Stuart Shafer · (888) 888-8888 · sshafer@geodysseyrsch.com

  • Paradigm Health System

    Slidell, LA 70458

    Site contact: Patrick Glynn, MD · 985-882-4500 · trickpatglynn@yahoo.com

  • Penn Medicine University City

    Philadelphia, PA 19104-5545

    Site contact: Sami Khella, MD · 215-662-8870 · sami.khella@pennmedicine.upenn.edu

  • Jefferson Health Honickman Center

    Philadelphia, PA 19107

    Site contact: Goran Rakocevic, MD · 857-350-4834 · clinicaltrials@argenx.com

  • University Neurology

    Knoxville, TN 37920-1511

    Site contact: Christopher Scheiner, MD · 865-521-6174 · cscheiner@utmck.edu

  • National Neuromuscular Research Institute

    Austin, TX 78756

    Site contact: Yessar Hussain, MD · 512-920-0140 · yessar@austinneuromuscle.com

  • NeuroCarePlus

    Houston, TX 77094

    Site contact: Nicolas Nammour, MD · 281-579-6800 · nicolas.nammour@sclamanagement.com

Study contacts (from the official record)

  • Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
All neurology studies in Alabama →
A Study to Assess the Efficacy and Safety of Empasiprubart in… (NCT07091630) | Bored Studies